You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Regeneron Pharmaceuticals Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Regeneron Pharmaceuticals Company Info
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
News & Analysis
It's not too late to get in on the potential 2023 growth for these two stocks.
Both of these companies have potential catalysts on the way.
These two durable companies can navigate the market downturn and beyond.
These biotech stocks are finding game-changing therapies, and their shares are up as a result.
These CRISPR stocks could be big winners for patient investors.
The biotech's crown jewel scores a key win in the clinic.
Has the healthcare stock been a better investment than the S&P 500?
These companies regularly post gross margins of 80% or better.
Regeneron Pharmaceuticals stock got a shot in the arm after it announced a possible drug candidate for coronavirus.
Key trials suggest doctors may change how they treat patients with cardiovascular disease.
Positive trial data unveiled at the American Society of Hematology conference makes these top stocks to watch in 2019.
With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.
REGN earnings call for the period ending September 30, 2021.
REGN earnings call for the period ending June 30, 2021.
REGN earnings call for the period ending March 31, 2021.
REGN earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.